Clinical Trials Logo

Filter by:
NCT ID: NCT03394365 Recruiting - Clinical trials for Stem Cell Transplant Complications

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

ALLELE
Start date: December 29, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

NCT ID: NCT03385187 Recruiting - Sleep Apnea Clinical Trials

Prospective Validation Study of a Novel Type IV Home Sleep Apnea Test

Start date: June 29, 2017
Phase: N/A
Study type: Interventional

Prospective validation study of the NightOwl, a Type IV home sleep apnea test (HSAT), compared to a traditional Type I and a Type IV sleep monitor.

NCT ID: NCT03378583 Recruiting - Clinical trials for Complication of Ventilation Therapy

Prevention of Gastric Insufflation During Positive Pressure Ventilation ?

Start date: March 22, 2017
Phase: N/A
Study type: Observational

Evaluation of a new method to prevent gastric insufflation

NCT ID: NCT03378557 Recruiting - Clinical trials for Periprosthetic Fractures

Periprosthetic Fracture Registry (PPFx)

PPFx
Start date: December 31, 2018
Phase:
Study type: Observational [Patient Registry]

This registry supports international data collection and research on PPFx treatments after hip and knee arthroplasty. A registry such as this ultimately aims to provide far-reaching benefits to society including reduced morbidity and mortality, improved patient safety, improved quality of care and medical decision-making, reduced medical spending, and advances in orthopaedic science.

NCT ID: NCT03377920 Recruiting - COPD Clinical Trials

Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's.

Start date: October 12, 2017
Phase: N/A
Study type: Interventional

The main aim is to study correlations between Peak inspiratory flow measured during a spirometry (PIFspiro) and Peak inspiratory flow measured over a pre-set resistance (PIFresist) in COPD patients and severe asthma patients. PIFresist will be measured using 5 different resistances, representing all DPI's relevant for the treatment of obstructive lung diseases. If this shows a distinct relationship between PIFspiro and PIFresist, PIFspiro cut-off points will be sought in an attempt to predict which patients are likely to be able to produce optimal flows for DPI use. If successful, this will make the actual measurement of PIFresist redundant in clinical practice. Also the relationship between PIFresist and device internal resistance in addition to PIFspiro (which corresponds to a very low resistance) will be examined.

NCT ID: NCT03368820 Recruiting - Lung Neoplasm Clinical Trials

Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry

Start date: December 4, 2017
Phase:
Study type: Observational [Patient Registry]

Therapeutic algorithms for lung cancer are mainly based on randomised controlled trials which excluded patients with severe co-morbidities. Smoking, the main risk factor for lung cancer, is associated with cardiovascular events that may impact on the therapeutic decision. The aim of this registry is to determine if and how cardiovascular co-morbidities impact on the physicians' decision for anticancer treatment in lung cancer patients by comparing it to the European Lung Cancer Working Party (ELCWP) guidelines

NCT ID: NCT03366545 Recruiting - Heart Failure Clinical Trials

Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

BIO|STREAM HF
Start date: May 14, 2018
Phase:
Study type: Observational [Patient Registry]

The registry is primarily designed to assess outcome, efficacy and residual safety aspects of CRT based on long-term data from an unselected, real-life clinical set-up. Moreover, the observation of the patient status should help to find possible predictors for HF events and to identify areas of improvement for CRT and for CRT device settings.

NCT ID: NCT03346369 Recruiting - Nephrolithiasis Clinical Trials

Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis

LaCa
Start date: August 18, 2017
Phase: Phase 3
Study type: Interventional

This study investigates the efficacy and the safety of Lanthanum Carbonate for the reduction of urinary oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis.

NCT ID: NCT03341793 Recruiting - Diabete Type 2 Clinical Trials

Impact of Changes in Muscle Secretome in the Remission of Type 2 Diabetes Mellitus Induced by Bariatric Surgery

MYDIASECRET
Start date: November 14, 2017
Phase: N/A
Study type: Interventional

Bariatric surgery is recognized as a therapeutic modality of type 2 diabetes. The mechanisms of this remission of diabetes remain poorly understood. The aim of our research is to characterize the changes in muscle secretome induced by bariatric surgery and to determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by the B cell responsible for the remission of diabetes.

NCT ID: NCT03331601 Recruiting - Carcinoma Clinical Trials

Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients

Start date: October 16, 2017
Phase: Phase 2
Study type: Interventional

This study investigates the uptake of the radiopharmaceutical 68-GaNOTA-Anti-HER2 VHH1 in brain metastasis using PET/CT imaging. Patients with HER2-positive and HER2-negative cancer will be included and the uptake in their lesions will be compared. Optional 68-GaNOTA-Anti-HER2 VHH1 scans may be performed during or after treatment, at time points 12±6 weeks and 24±9 weeks after the first scan.